Technical Data Sheet
Tirzepatide
Also Known As: LY3298176, Tirzepatide peptide, GIP GLP-1 dual agonist, Eli Lilly dual agonist, Twin incretin, Twincretin, GLP-1 GIP tirzepatide, Mounjaro injection, Zepbound injection, Tirzepatide LY3298176, Dual incretin obesity drug, Tirzapatide, Tirzepetide, GIP/GLP-1, twincretin, tirz, tzp
Scan To View Profile
| Evidence Tier | Approved Drug |
|---|---|
| Category | Weight Loss & Metabolism |
| Class | Dual GIP/GLP-1 receptor co-agonist (twincretin); synthetic 39-residue peptide with C18 fatty diacid for albumin binding |
| Molecular Target | GIPR (GIP receptor) + GLP-1R (GLP-1 receptor); dual incretin axis activation; pancreatic insulin secretion and hypothalamic appetite suppression |
| Sequence | 39-aa acylated peptide (C20 diacid) |
| Molecular Weight | ~4814 g/mol |
| CAS | 2023788-19-2 |
| Parent | Incretin dual agonist |
| Mechanism | It is a dual GIP and GLP-1 receptor agonist. It dramatically slows gastric emptying and sensitizes the body to insulin, resulting in profound appetite suppression and record-breaking weight loss in trials. |
| Studied For | Type 2 diabetes management, Chronic weight management / obesity, Obstructive sleep apnea in obesity (FDA approved 2024), Non-alcoholic fatty liver disease (NAFLD/MASH), Cardiovascular risk reduction, HbA1c lowering, Body weight reduction superior to semaglutide, Insulin resistance, Metabolic syndrome, Polycystic ovary syndrome, Kidney disease in diabetes, Heart failure with obesity, Appetite suppression dual pathway, Lean mass preservation, weight loss, diabetes, fat loss, appetite suppression, obesity, metabolic syndrome, insulin sensitivity, A1C reduction |
| Administration Route | Injection Only |
| Form | lyophilized (research) or pen/vial |
| Diluent | bacteriostatic water |
| Storage Temperature | Refrigerate 36-46°F |
| Light Sensitive | Yes |
| Freeze / Thaw | avoid |
| Reconstituted Shelf Life | 28 Days |
| Handling Notes | Avoid freeze-thaw, heat, and shaking. |
| Regulatory | FDA-approved: Mounjaro (T2D, 2022); Zepbound (chronic weight management, 2023); Zepbound approved for moderate-to-severe obstructive sleep apnea in adults with obesity (Dec 2024). Compounded versions are not FDA-evaluated. Not on the WADA 2026 Prohibited List; tirzepatide was added to the WADA Monitoring Program effective 1 January 2026 (monitored, not sanctioned). |
| Sources |